Skip to content

Y-mAbs Therapeutics, Inc.

CIK 0001722964

← back to feed
Revenue (TTM)
$81.69M
+3.4% YoY Q2 Aug 2025
Net Income (TTM)
−$24.68M
−38.5% YoY Q2 Aug 2025
EPS Diluted (TTM)
−$0.56
−36.7% YoY Q2 Aug 2025
Gross Margin
88.6%
Q2 Aug 2025
Operating Margin
-37.3%
Q2 Aug 2025
Net Margin
-30.2%
Q2 Aug 2025
Free Cash Flow (TTM)
−$49.12M
Q2 Aug 2025
Cash
$62.29M
Q2 Aug 2025
Total Debt
—
Q2 Aug 2025
Shares Outstanding
45.44M sh
Q2 Aug 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings